My-Cardia

AWS Cloud-Based Web Portal

My-Cardia web portal provides 24/7 AWS cloud-based access featuring innovative devices and software to simplify 30-day event monitoring for both patients and Physicians.

Connect

The MyCardia AT recorder can be used continuously for up to 30 days. In addition the device is intended for single use for each patient enrolled.

Record

The MyCardia AT recorder is very small, discreet and has only one button to manually record and transmit ECGs. The unique auto-trigger enables automatic recording of asymptomatic events detected by the algorithm for atrial fibrillation, tachycardia, bradycardia and pauses.

Send

Our AWS cloud-based web portal provides easy and secure access for reviewing and or printing reports from anywhere. Information can be viewed using computers, tablets, and smart phones.

Cardiac Biotech Solutions, Inc. (OTCID: CBSC) is a medical device company focused on non-invasive ambulatory cardiac monitoring, supported by cloud-based software and mobile applications.

The Company’s flagship product, MyCardia AT, is designed to assist physicians in the detection and evaluation of cardiac arrhythmias during extended monitoring periods.

Key Regulatory & Commercial Milestones

  • United States: The Company has received clearance from the U.S. Food and Drug Administration for its MyCardia AT cardiac event monitoring device, enabling commercial distribution in the U.S.
  • Canada: The Company has received a Medical Device License (MDL) from Health Canada for MyCardia AT (marketed in Canada as CardioHolter AT), permitting import and commercialization.
  • Commercialization: The Company has announced initial distributor purchase orders and commercial agreements in Canada and international markets.
  • International Expansion: The Company is advancing regulatory and distribution initiatives in additional international markets, including China, in collaboration with manufacturing and distribution partners.

Learn more about the innovative, MyCardia AT!

Get our news in your inbox!

Join our newsletter and we will send our news directly to you.